Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

7MW 3711

Next Previous
Drug Profile

7MW 3711

Alternative Names: 7MW-3711

Latest Information Update: 25 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mabwell (Shanghai) Bioscience
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Small cell lung cancer; Solid tumours

Most Recent Events

  • 21 Sep 2026 Mabwell (Shanghai) Bioscience plans a phase III trial for Squamous cell carcinoma of lungs (Inoperable/unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China in October 2026 (IV) (NCT07831863)
  • 11 Feb 2026 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT07466160)
  • 12 Sep 2025 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease) in China (IV) (Mabwell (Shanghai) Bioscience pipeline, September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top